Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Venetoclax · 1 trial · 2 indications
Assessed by flow cytometry (FC)
| Arm | Type | Description |
|---|---|---|
| Cohort A: BTKi and BCL2i naive | EXPERIMENTAL | Participants who have never received a BTK inhibitor or a BCL-2 inhibitor |
| Cohort B: BTKi or BCL2i exposed without disease progression | EXPERIMENTAL | Participants who have received prior treatment with a BTK or BCL-2 inhibitor and discontinued treatment for any reason other than disease progression |
| Cohort C: BTKi exposed and with disease progression | EXPERIMENTAL | Participants who experienced disease progression on a prior BTK inhibitor. Participants with BTK C481X mutation at enrollment will be excluded. |
| Name | Type | Description |
|---|---|---|
| Venetoclax | DRUG | C4-15 |
| Zanubrutinib | DRUG | C1-15 |
Inclusion Criteria * Confirmed diagnosis of CLL or SLL as per 2018 International Workshop on CLL (IWCLL) criteria. * Participants must have relapsed after at least one prior line of therapy and must currently require therapy by 2019 IWCLL criteria. * For enrollment to Cohort A: Participants must be...
Venetoclax is an investigational small molecule being studied for the treatment of Chronic Lymphocytic Leukemia (CLL). It is currently in Phase 2 clinical development. The drug is being evaluated in combination with zanubrutinib in a clinical trial for patients with CLL and Small Lymphocytic Lymphoma.
Venetoclax targets the B-cell lymphoma 2 (BCL-2) protein, which is involved in regulating apoptosis. By inhibiting BCL-2, Venetoclax promotes the death of cancer cells. This mechanism is being studied in the context of Chronic Lymphocytic Leukemia, where the drug is evaluated in a Phase 2 clinical trial.
Venetoclax is being developed by BeOne Medicines Ltd., a company listed on the stock exchange under the ticker ONC. The company is conducting a Phase 2 clinical trial of Venetoclax in Chronic Lymphocytic Leukemia. The trial is currently recruiting participants in the United States.
Venetoclax is in Phase 2 clinical development for Chronic Lymphocytic Leukemia. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting patients and is designed to evaluate the drug's safety and efficacy.
Venetoclax is being studied in a Phase 2 clinical trial with the identifier NCT05168930, titled 'Zanubrutinib and Venetoclax in CLL (ZANU-VEN)'. This trial is recruiting 45 participants with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the United States. The study is controlled but not randomized or double-blinded.
No, Venetoclax is not the same as zanubrutinib. Venetoclax is a small molecule that targets BCL-2, while zanubrutinib is a separate drug that inhibits Bruton's tyrosine kinase (BTK). In the ongoing Phase 2 clinical trial, Venetoclax is being studied in combination with zanubrutinib for the treatment of Chronic Lymphocytic Leukemia.